Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04195659 · ClinicalTrials.gov registry record
Chest Dysphoria in Transmasculine Spectrum Adolescents
A clinical trial, sponsored by Northwestern University.
- Completed
- Registry status
- 81
- Enrollment target
NCT04195659: Completed study, sponsored by Northwestern University.
NCT04195659 is a clinical trial that has completed, run by Northwestern University. The registered enrollment target is 81 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04195659 has completed, sponsored by Northwestern University.
- COMPLETED
- Registry status
- 81 participants
- Enrollment target
Study Summary
The investigators hypothesize that masculinizing top surgery (e.g., mastectomy and chest masculinization) leads to an improvement in self-report chest dysphoria, gender dysphoria, and gender congruence in assigned-female-at-birth, transgender and non-binary youth and young adults. This is a prospective, observational study that will enroll assigned-female-at-birth, transmasculine spectrum individuals age 13 to 25 years old who are or are not undergoing top surgery. Participants will complete a set of standard of care questionnaires regarding their chest dysphoria (e.g., distress about the chest), gender dysphoria (e.g., distress about a gender identity that does not match assigned sex), and gender congruence (e.g., degree to which an individual feels they are living in their authentic appearance and gender identity). They will complete this same set of questionnaires either three months after their top surgery or three months after the initial set of surveys.
Primary Outcome
The disruption of individual comfort, physical functioning, and interpersonal relationships from a chest with breasts, as measured by the Chest Dysphoria Measure (Score 0-51, Higher number means greater chest dysphoria)
Interventions
- PROCEDURE Mastectomy and chest masculinization
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 81 participants |
| Start Date | 2019-10-29 |
| Est. Completion | 2021-12-31 |
What the finished NCT04195659 record still lists
NCT04195659 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 81 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Mastectomy and chest masculinization is the first listed.
NCT04195659 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04195659 about?
NCT04195659 is a clinical study titled "Chest Dysphoria in Transmasculine Spectrum Adolescents". The investigators hypothesize that masculinizing top surgery (e.g., mastectomy and chest masculinization) leads to an improvement in self-report chest dysphoria, gender dysphoria, and gender congruence in assigned-female-at-birth, transgender and non-binary youth and young adults. This is a prospect...
What is the current status of trial NCT04195659?
This trial is currently completed. The enrollment target is 81 participants. The study started on 2019-10-29. Estimated completion is 2021-12-31.
What interventions are being tested in trial NCT04195659?
The interventions under investigation include: Mastectomy and chest masculinization (PROCEDURE).
Who is sponsoring clinical trial NCT04195659?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04966481 · 81 participants · Phase 3
Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 Inhibitor
- NCT05109429 · 81 participants · NA
Developing a Clinical Outcome Assessment for Opioid Craving
- NCT05112601 · 81 participants · Phase 2
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
- NCT05305911 · 81 participants · Phase 2
Sodium Glucose Co-Transporter 2 (SGLT2) and STEMI
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI